Title : Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.

Pub. Date : 2022 Jun

PMID : 35074264






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. olaparib BRCA1 DNA repair associated Homo sapiens
2 Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. olaparib BRCA1 DNA repair associated Homo sapiens
3 This study examines the use of olaparib in patients with metastatic breast cancer harboring sBRCA1/2 or germline or somatic non-BRCA1/2, HRR mutations and demonstrates potential activity of PARPi in this setting. olaparib BRCA1 DNA repair associated Homo sapiens
4 METHODS: In this retrospective, single institution study, patients who were treated with off-label, off-protocol olaparib for metastatic breast cancer harboring sBRCA1/2 or germline or somatic non-BRCA1/2, HRR mutations were identified. olaparib BRCA1 DNA repair associated Homo sapiens